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Cardiovascular implants must resist thrombosis and intimal hyperplasia to maintain patency. These implants when in contact
with blood face a challenge to oppose the natural coagulation process that becomes activated. Surface protein adsorption and
their relevant 3D conﬁrmation greatly determine the degree of blood compatibility. A great deal of research eﬀorts are attributed
towards realising such a surface, which comprise of a range of methods on surface modiﬁcation. Surface modiﬁcation methods
can be broadly categorized as physicochemical modiﬁcations and biological modiﬁcations. These modiﬁcations aim to modulate
platelet responses directly through modulation of thrombogenic proteins or by inducing antithrombogenic biomolecules that
can be biofunctionalised onto surfaces or through inducing an active endothelium. Nanotechnology is recognising a great role in
such surface modiﬁcation of cardiovascular implants through biofunctionalisation of polymers and peptides in nanocomposites
and through nanofabrication of polymers which will pave the way for ﬁnding a closer blood match through haemostasis when
developing cardiovascular implants with a greater degree of patency.
1.Introduction
Cardiovascular disease accounts for a signiﬁcant percentage
of mortality and morbidity in the ageing population and
has an estimated increase in the coming years [1]. There is
an urgent clinical need for improved cardiovascular devices,
which mainly include vascular bypass grafts, vascular stents,
and heart valves, which will promote desirable blood-
biomaterial interactions with a high patency. Vascular occlu-
sive disease holds the greatest risk factor most emphasised
in the coronary arteries where cardiac ischemia may lead
to complete heart failure. Main reperfusion-based surgical
intervention options for these diseases involve angioplasty,
stenting, endarterectomy, and bypass graft surgery depend-
ing on the degree of occlusion. Cases with greater than
70% occluded arteries are required to be treated with bypass
grafts. For small diameter bypass grafts, autologous bypass
conduits are preferred for primary revascularisation [2].
However, 3–30% patients are presented with no autologous
vessels due to previous disease conditions and thus there
is a need for vascular grafts which could perform closely
to autologous vessels [3]. Graft thrombogenicity due to
material surface incompatibility and altered ﬂow dynamics
at the site of anastomosis or distal outﬂow are recognised
as primary reasons for blood contacting device failure [4].
There is a great interest in research strategies that focus
upon surface techniques by modifying the physicochemical
properties at the implant surface [5] and by combining
a biomimetic approach through functionalisation which
presents an exciting challenge to improve patency rates
clinically (Figure 1). This paper aims to review some of the
signiﬁcant approaches in modifying a material surface to
create optimal interactions with blood.
2.Blood-ImplantSurface
Interactions: Thrombogenicity
The initial events leading to thrombosis surrounding the
tissue-implant interface are mediated by surface interactions
with adsorbed proteins (intrinsic pathway) or through the
release of tissue factor (TF) from damaged cells at the site of2 International Journal of Biomaterials
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Figure 1: Haemocompatibility-determining factors in a cardiovas-
cular device; marked in red are areas of interest in this paper.
injury (extrinsic pathway) [6]( Figure 2). The intrinsic path-
wayisindependentofinjury.Adsorbedsurfaceproteinsform
a complex composed of collagen, high molecular weight
kininogen (HMWK), prekallikrein, and factor XII. Inactive
precursors (clotting factors) change conformation and are
converted into active enzymes via a biochemical cascade
resulting in platelet activation (with the aid of additional
cofactors). Cleavage of prothrombin via the prothrombinase
complex bound to cellular membranes generates thrombin,
and by converting ﬁbrinogen to ﬁbrin, forms a stable
insoluble gel (red thrombus or clot).
Vascular injury and damage to the endothelium releases
TF, collagen, and von Willebrand factor (vWF) to initiate the
extrinsic pathway. Clotting factors interact with platelet sur-
face receptors and play a fundamental role in the interaction
of collagen to initiate thrombosis, release growth factors and
cytokines to enhance the coagulation cascade and strengthen
the haemostatic plug. The platelets change morphology and
agglomerate forming a thrombus layer. It is important to
note that both pathways converge during the formation of
theprothrombinasecomplexleadingtothrombingeneration
referred to as the common pathway.
Vascular procedures such as arteriovenous graft place-
ment and angioplasty damage the adventitial and medial
tissues of the arterial wall with injury to the endothelium
lining the intima [4]. For example, angioplasty is a con-
trolled traumatic event, which is aimed at causing plaque
rupture by widening a narrowed or obstructed vessel. These
processes can expose otherwise intact subendothelial matrix
removing the protective endothelium and expose medial
smooth muscle cells (SMC) directly to blood ﬂow, and other
procoagulants and proinﬂammatory blood constituents.
Tissue trauma rapidly initiates the recruitment of inﬂam-
matory cells that release potent cytokines and promote SMC
migration and proliferation. The anticoagulant and vascular
protective functions of intact endothelium from prostacyclin
(PGI2) and nitric oxide (NO) required for the regulation of
blood ﬂow soon diminish [7]. Both molecules are necessary
to inhibit platelet adhesion, aggregation and activation to the
endothelium and SMC, which are considered early events in
the development of intimal hyperplasia (IH). Furthermore,
NO inhibits SMC proliferation and migration. In addition,
the adventitial layer is partially removed for creating the
anastomosis during surgery depriving the vessel wall of
oxygen and vital nutrients [8].
Almost all materials are considered to be thrombogenic
with the exception of the endothelial cell (EC) layer, which
lines the vasculature. Large diameter vascular grafts were
originally thought to be antithrombogenic in nature. For
example, expanded polytetraﬂuoroethylene (ePTFE) bypass
grafts appear nonthrombogenic due to the high ﬂow rates
of blood past the luminal surface, but in reality, all are
thrombogenic to a certain degree.
In healthy individuals the ﬂow of blood is laminar but
when compared with diseased or occluded arteries may often
be transitional or even turbulent in behaviour. At the blood-
biomaterial interface, haemodynamic forces of shear stress
at the wall surface play a critical role in blood contacting
devices and inﬂuence protein adsorption [9], platelet and
leukocyte adhesion. Leukocytes recognise speciﬁc proteins
and adhere under ﬂowing conditions to initiate further
cell signalling and recruitment events. A study evaluating
leukocyte adhesion on polyurethanes materials has shown
that cell density decreased with increasing shear stress.
Certain shear stress models have been studied (particular
when applied to seeded vascular grafts) to promote EC
retention and found to correlate with changes in the EC
phenotype [10]. Various strategies exist to inhibit these
processes and prolong graft patency, including modiﬁcation
of grafts with various anticoagulants (heparin), antiplatelet
factors (glycoprotein IIb/IIIa inhibitors), and antiproliferat-
ingagents(rapamycin).Inthefollowingsectionsweconsider
diﬀerentsurfacemodiﬁcationtechniquesthataredesignedto
minimise complications that arise at the blood-biomaterial
interface.
3. Role of Proteinsin Optimal
Blood-Biomaterial Interactions
Cardiovascular implants, in the body, are subjected to
the “Vroman eﬀect” [11] which highlights the dynamic
interactions with water and proteins to synthetic material.
Thiseventisrapid(<1sec),leadingtotheformationofathin
proteinﬁlmintheorderofnanometersinthickness[12].The
adsorption of proteins (composed of polar, nonpolar, and
chargedsidegroups)contributestothesurfaceactivity.Once
p r e s e n ta tt h es u r f a c e ,p r o t e i nm o l e c u l e si n t e r a c tw i t hw a t e r ,
electrolytes, and the underlying surface chemistry (and
energy) of the material through hydrogen bonding, van der
Waals, pi-pi (π-π) stacking, and electrostatic interactions.
Exactly which force governs the interaction of proteins on
surfaces depends upon the particular protein and other
factors including size, charge, conformation, and unfolding
rate described by Vroman [13]. Chemical and physical
properties of the materials, for example, surface chemistry,
energy (charge) and topography, inﬂuence the interfacialInternational Journal of Biomaterials 3
Implantation of VG
Contact activation (intrinsic) pathway
Damaged 
surface
Tissue factor 
(extrinsic) pathway
XII XIIa
XI XIa
IX IXa
X
Xa
Va
Prothrombin
(II)
Thrombin
(IIa)
V
Active protein C
Protein S
Fibrinogen
(I) 
Fibrin
(Ia)
XIIIa XIII
Trauma
TFPI
VIIa VII
Tissue factor Trauma
Antithrombin
Common
pathway 
X
VIII
VIIIa
Protein C+
thrombomodulin
(B) Midstage cascade:
(1) thrombin assay (TGA)
(2) ﬁbrinogen reagent
(A) Early stage cascade:
(1) prekallikrein assay
(2) ELISA: factor XII
Cross-linked
ﬁbrin clot
(C) Late stage cascade:
(1) ELISA: Human sP-selectin
(2) Human CXCL4/PF4
(D) End stage cascade:
cell adhesion,
platelet activation,
and aggregation
(E) Tissue response:
inﬂammation,
e.g., interleukins
(3) elisa: ﬁbrinopeptide A
(2)
vWF
Collagen
Resting platelets
Adhesion
Fibrinogen
Aggregation
α-granule release (PF 4)
(1)
(3) WBCs, RBCs...
Figure2:Intrinsicpathwayofbloodcoagulation:highlightedarethemainfactorswhichareinvolvedinbloodcoagulation.Numberedevents
distinguish as (1) biochemical, (2) platelets, and (3) whole blood (red and white blood cells). Image is adapted from http://en.wikipedia
.org/wiki/File:Coagulation full.svg.
behaviour adjacent to the biomaterial. The interfacial region
at the blood-biomaterial surface continually alters and
redistributes the protein/electrolyte/water layer, and the host
cells and tissues react to changes in this layer. Material
surfaces with zero interfacial energy and reduced enthalpic
and entropic eﬀects do not strongly support cell/thrombin
adhesion [14]. Surface wettability of a biomaterial is highly
signiﬁcantand,inadditiontodiﬀerentialproteinadsorption,
platelets respond diﬀerently to hydrophobic or hydrophilic
monomers [15].
Adsorption of plasma and extracellular matrix (ECM)
proteins (ﬁbrinogen, albumin, and γ-globulin), and to a
lesser degree ﬁbronectin, collagen, vWF, coagulation factors
XI and XII, and HMWK play a crucial role in balancing
thrombosis and haemostasis [16]. Such proteins direct and
aid the adhesion of red blood cells, platelets (the ﬁrst cellular
components to adsorb to the protein ﬁlm), followed by
leukocytes, and EC. The cellular components interact with
the protein layer to guide migration, initiate blood coagula-
tion, and stimulate cell proliferation and diﬀerentiation, as
speciﬁc proteins present binding sites for macromolecules
and receptors guiding the recruitment of further cells in-
teracting within the vasculature.
Protein adsorption and subsequent cell attachment and
behaviour in response to an implanted foreign material is
determined by a variety of material properties including sur-
face chemistry, topography, dissolution rate, and the micro-
/macromechanical elasticity. Material surface properties can
therefore be modiﬁed by physicochemical modiﬁcation
and/or biofunctionalisation to promote desirable protein
and cellular interactions. Figure 3 summarizes the main
mechanisms, which inﬂuence blood compatibility.
4. Surface Modiﬁcation of
Blood ContactingMaterials
Much eﬀort has focused on surface modiﬁcation to optimise
antithrombogenic surface properties and two approaches
exist in the development of cardiovascular grafts. The
ﬁrst approach involves the design of a permanent vascular
replacement, which has a nonadhesive, inert, nonbiofouling
surface. Physicochemical methods have been applied to
achieve this aim using electrochemical polishing, surface
roughening, ordered patterning, plasma treatment [17],
chemical etching, and passive or covalent surface coatings.
The second approach aims to functionalise the grafts in such
a way that it facilitates (or activates) a cascade of biological
events which eventually regenerates or replaces functioning
tissue. Biofunctionalisation of surfaces is a popular research
theme, which relies on the tools of biology to create
biomimetic surfaces to incorporate biologically active (or
inactive) molecules to generate speciﬁc response(s) [18–22].
Figure 4, Table 1 present a summary of the principle
methods in applied surface modiﬁcation techniques. In this
way,surfacemodiﬁcationcanbedirectedtowardsoptimising
the following: (1) protein adsorption (2), the generation of
thrombin (and its formation leading to blood coagulation),4 International Journal of Biomaterials
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Figure 3: Main mechanisms inﬂuencing blood compatibility.
(3) platelet adhesion (followed by aggregation and activa-
tion),and(4)cellularbehaviouratthesurfaceoftheprosthe-
sis. All strategies are designed to optimise patency-limiting
thrombogenic events at the blood-biomaterial interface. For
example, vascular graft endothelialisation has been high-
lighted as the ultimate solution to address thrombogenicity,
and its associated complications.
4.1. Physicochemical Modiﬁcation. A range of physical tech-
niques has been applied to modify the surface topography
of vascular graft materials. Topography on the micron and
nanometre scale is an important physical property, which
inﬂuences protein adsorption, platelet adhesion, thrombo-
genicity, and cell behaviour [23]. The inclusion of pores,
pits, and groves become unavoidable at this scale during
the manufacturing process of blood contacting devices. For
example, a recent study revealed that the surface roughness
of ePTFE graft luminal surfaces was signiﬁcantly higher
(147.0nm)whencomparedwithexternalsurfaces(1.74nm).
Plasma proteins such as ﬁbrinogen have been shown to
adhere to nanostructures and bind to platelet receptors more
eﬃciently than ﬂat structures [24]. Albumin, ﬁbrinogen,
and ﬁbronectin all interact with a dialysis membrane’s
surface topography, which plays a crucial role in the adsorp-
tion process. Such surfaces have been shown to promote
ﬁbronectin and vitronectin adsorption and direct a cascade
of interactions from the blood and surrounding tissues.
Surface porosity is a crucial factor when considering the
topography of vascular graft materials [25]. A recent study
looked at the eﬀect of porosity (ranging from 5 to 90μmi n
diameter) on EC growth. It was found that EC cell growth
was enhanced by smaller pores (5–20μm in diameter) and at
a lower interpore distances.
Changing the surface topography on the micron and
nanometre scale also lead to localised changes in surface
chemistry as both physicochemical cues are intrinsically
linked. The primary aim of topographical and chemical sur-
face modiﬁcation is to encourage desirable protein, cellular,
and tissue interactions at the blood-biomaterial interface,
thus improving patency and performance of the material,
since all are known contributory factors that inﬂuence
thrombogenicity.Nanocompositematerialsarerecognisedto
oﬀer favourable solutions as biomaterials for cardiovascular
implants. Nanocomposite polymers in general have found
to be amphiphilic, thermodynamically stable and, when
used in vascular bypass graft development, they have shown
to exert novel advantageous properties such as favourable
blood response [27], biostability [28], and enhanced
mechanical properties compared to grafts with conventional
material. While being viscoelastic, polyhedral-oligomeric-
silsesquioxane-poly(carbonate-urea)urethane (POSS-PCU)
has been shown to have strength similar to natural arter-
ies. POSS-nanocomposite polymer, used for cardiovascular
implants, which include vascular bypass grafts, stents, and
heart valves has been proved to have antithrombogenic
properties [29].
Nonfouling surfaces have been used to prevent pro-
tein adsorption and platelet adhesion. Much eﬀort has
focused upon the passivation of materials using polymers
to achieve a nonadhesive, nonbiofouling surfaces such as
PEG (polyethylene glycol), hydrogels (containing dextran),
and PEO (polyethylene oxide). For example, ePTFE grafts
have been coated with polypropylene sulphide (PPS)-
PEG and evaluated in arteriovenous models. This study
included heparinised and nonheparinised graft perfusion
and evaluated cell adhesion and thrombus formation. No
diﬀerence was observed in cell adhesion when compared
with controls; however, the surface coating signiﬁcantly
decreased thrombus formation when used in conjunction
with heparin. Dextrans (hydrophilic polysaccharides) show
a similar eﬀect to PEG with regard to protein adsorption.
Dextrans, PEG, and PEO can be further chemically modiﬁed
along the polymer backbone with cell-selective peptides to
promote speciﬁc cell adhesion. Spin coating of the luminal
surfaceofePTFEwasrecentlyachievedusingabiodegradable
elastomer poly(1,8-octanediol citrate) (POC). The POC
coatings had no eﬀect on graft compliance and delayed
thrombosisinvitrowhencomparedwithcontrols.Thisstudy
highlighted that POC-ePTFE grafts maintained EC adhesion
and proliferation of porcine cells similar to that of the native
tissues, and within 10 days the EC was conﬂuent, while only
random patches were evident on ePTFE controls.
4.2. Biofunctionalisation
4.2.1. Endothelialisation. The endothelium is in intimate
contact with the blood ﬂow and consists of a single layer
of EC, which functions as a dynamic organ and covers the
entire surface of the circulating system from the heart to
the smallest capillary. Endothelialisation of cardiovascularInternational Journal of Biomaterials 5
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Figure 4: Examples of various physical, chemical, and biofunctionalisation techniques to enhance haemocompatibility. Biofunctionalised
surfaces interact with cell surface receptors, that is integrins. Whereas physiochemical modiﬁcation can inﬂuence cell-material interactions
through charge, topography, and attractive/repulsive forces due to hydrophobic and hydrophilic interactions [26].
Table 1: Summary of the various modiﬁcation techniques currently employed for optimising blood-material interactions [26].
Modiﬁcation Description
Physical immobilisation
Polymer gelling (growth factor mixed with the material in the liquid state and change temp, pH or ion
concentration to obtain a gel with nanopores)
Emulsion techniques (factors which are insoluble in aqueous solutions)
High pressure gas foaming (incorporate GF into porous scaﬀolds, without the use of solvents)
Covalent modiﬁcation Surface distribution of ligands
Distribution of ligands through the bulk of the material
Surface adsorption
Passive adsorption driven by secondary interactions between the molecule and the protein
Self-assembled monolayers (SAMs) adsorption of the peptide (which is designed with hydrophobic tail
and a spacer) from solution
Microcontact printing of alkanethiol SAMs, photolithography (on hard materials), soft lithography (on
elastomeric materials)
Direct protein patterning: drop dispensing, microﬂuidic patterning
Crosslinking Photo/chemical crosslinking
Altering surface wettability
Ion bombardment
UV irradiation
Exposure to plasma discharge
Altering surface roughness Deposition of polymer ﬁlms/islands, nanoparticles, metallographic paper or diamond paste polishing,
sand blasting, photolithography, and e-beam etching
implants is considered most favourable as this would protect
the vessels by producing natural biochemicals, for example,
NO for vasoprotection. There is a great deal of research
involved in inducing endothelialisation of cardiovascular
implants and insitu endothelialisation is considered to be
most favourable. This need for insitu endothelialisation has
led to a considerable interest in stem cells which have
the potential to induce endothelialisation. This interest in
endothelial progenitor stem cells inturn has given rise to
an exciting area of research on “stem cell technology” for
vascular grafts.
Stem cells/EPC are on the threshold of realising their
great potential in cardiovascular therapy and stem cell in-
teractions with various biomaterials which have been exten-
sively studied [30–34]. Cells are inherently sensitive to
physical, biochemical, and chemical stimuli from their
surroundings. Cells are in intimate contact with the ECM,
which is formed from a complex connection of proteins,
glycoproteins, and proteoglycans. The ECM provides not
only structural support but also contains a reservoir of cell
signalling motifs (ligands) and growth factors that guide
cellularanchorageandbehaviour.Thelocalcellenvironment6 International Journal of Biomaterials
or “niche” provides deﬁned environmental cues that deter-
mine cell-speciﬁc behaviour, including selective recruitment,
proliferation, diﬀerentiation, and the production of the
numerous proteins needed for hierarchical tissue organisa-
tion. The plethora of ECM compositions contain insoluble
macromolecules ﬁbrillar proteins (e.g., collagen) and glyco-
proteins (e.g., elastin, ﬁbronectin, laminin) which interact
with proteins on cell surfaces and soluble macromolecules
such as growth factors. The organisation, density, spatial
geometry, and biochemistry of these ECM components
determine mechanical strength, cell response, and ultimately
hierarchical tissue organization.
Features of the ECM such as nanoscale topography,
optimised mechanical properties, and presentation of bio-
responsive motifs have inspired multiple examples of bioma-
terials design for tissue engineering scaﬀolds. One strategy
in vascular research is to present endothelium-derived
macromolecules or their cell interacting domains onto
vascular grafts to mimic these features of the ECM and to
assist speciﬁc cell adhesion. Bioresponsive vascular grafts
can target several biological processes to promote insitu
endothelialisation including: (1) promoting the mobilisation
of EPC from the bone marrow, (2) encouraging cell-speciﬁc
(circulating EC, EPC, and/or stem cells) homing to the
vascular graft site, (3) providing cell-speciﬁc adhesion motifs
(peptides) on the vascular grafts (of a predetermined spatial
concentration), and (4) directing the behaviour of the cells
after adhesion to rapidly form a mature, fully functioning
endothelium capable of self-repair.
Optimal cell attachment, migration, proliferation, and
diﬀerentiation on a biomaterial require a surface which
mimics the natural ECM. Natural ECM proteins range in
diameterfrom50–500nm.Thesigniﬁcanceofmimickingthe
ECM,whichfacilitatestheinteractionswiththecellreceptors
suchasintegrins,hasbeendiscussed.Thisalsorecognisesthe
eﬀect of peptides such as RGD [35], which are derived from
functional domains of ECM components and their eﬀects
on enhancing accelerated endothelialisation. Nevertheless,
nonreceptor-mediated interaction of ECM such as porosity,
3D spatial arrangement also has a great inﬂuence in cell
interaction.
The microtopography of scaﬀold materials is not entirely
ideal for vascular cells, particularly EC as they are naturally
placed in a nanometre scale environment. Nanotopography
surfacescreatedbysurfacerougheningofarangeofmaterials
including polymers have shown enhanced cellular adhesion
[36–40]. Recent reviews have discussed various nanotech-
niques which could potentially be applied to vascular graft
engineering. Nanostructures has been shown to facilitate
protein interactions which then promote cell adhesion
[9, 41, 42]. Some of these proteins are selective such as
vitronectin and ﬁbronectin where they mediate enhanced
vascular cell interactions with the polymer [37, 38]. Three
main nanotechnology approaches, electrospinning [43, 44],
self-assembly,andphaseseparation,helptocreatenanoﬁbres
and to create a nanoarchitecture bypass graft surface for
optimal cell interactions [45].
In addition to mimicking an ECM, research has looked
into antibody-mediated stem cell recruitment as a rather
impressive approach in stem cell technology for applications
in vascular graft endothelialisation. EC and EPC have been
found to express CD34+, and therefore CD34+ antibodies
can be attached onto bypass graft surfaces to facilitate
interaction between graft and progenitor cells. Antihuman
CD34 monoclonal antibodies (IgG2a, epitope class III) were
immobilised to the ePTFE graft material (Orbus Medical
Technologies) with a proprietary multistep process.
In additional, furtherstudies have shown that superpara-
magnetic nanoparticles labelled endothelial cells can be used
to obtain an endothelial cell lining, for instance, as on the
luminal surface PTFE tubular grafts, coated with ﬁbronectin
with the aid of a customized electromagnet [46].
4.2.2. Antithrombogenic Surfaces Independent of an Endothe-
lium. The cardiovascular protective role of the endothelium
is recognized to be attributed to NO. Therefore, there is a
great interest in inducing NO from cardiovascular implants
and this has recently been reviewed in depth [47]. Recent
reviews have also detailed numerous anticoagulant and
antiplatelet agents that include, heparin, warfarin, hirudin,
dipyridamole clopidogrel, aspirin, cilostazol, and glycopro-
tein IIb/IIIa inhibitors (abciximab, eptiﬁbatide, tiroﬁban),
which are clinically used in addition to their applications in
engineered vascular graft surfaces [4, 48].
5.SummaryandFuturePerspective
Blood contacting materials, which are used to fabricate
cardiovascular implants, are expected to preferably promote
endothelial adhesion but resist other blood cell adhesion
that can give rise to thrombosis and intimal hyperplasia. A
greater understanding of the interactions of blood proteins
withmaterial surfaceswillenable better designing of surfaces
for blood contact. Surface modiﬁcations of materials will
be highly inﬂuenced by nanotechnology as this enables
to impart favourable properties without inﬂuencing the
structural and mechanical properties of the base material,
which forms the structure of a device of interest. It is also
of signiﬁcance that a particular surface modiﬁcation should
be always tailored to the implant of interest and should
be tested for its eﬃcacy in physiological haemodynamic
conditions. We believe that a reasonable progress has been
made in the search for optimal blood contacting materials,
but research into NO eluting polymers, endothelialisation,
and nanotechnology associated with surface modiﬁcation of
such materials may promise more sophisticated solutions in
the quest for optimal blood compatibility.
References
[1] S. Allender and M. Rayner, “Coronary heart disease statistics;
British Heart Foundation,” Heart Statistics, 2007, http://www.
bhf.org.uk/heart-health/statistics.aspx.
[2] M.Desai,A.M.Seifalian,andG.Hamilton,“Roleofprosthetic
conduits in coronary artery bypass grafting,” European Journal
of Cardio-Thoracic Surgery, vol. 40, no. 2, pp. 394–398, 2011.
[3] M. S. Baguneid, A. M. Seifalian, H. J. Salacinski, D. Murray,
G. Hamilton, and M. G. Walker, “Tissue engineering of bloodInternational Journal of Biomaterials 7
vessels,” British Journal of Surgery, vol. 93, no. 3, pp. 282–290,
2006.
[4] S. Sarkar, K. M. Sales, G. Hamilton, and A. M. Seifalian, “Ad-
dressing thrombogenicity in vascular graft construction,”
Journal of Biomedical Materials Research, vol. 82, no. 1, pp.
100–108, 2007.
[5] M. D. Mager, V. Lapointe, and M. M. Stevens, “Exploring and
exploitingchemistryatthecellsurface,”NatureChemistry,vol.
3, no. 8, pp. 582–589, 2011.
[6] M. B. Gorbet and M. V. Sefton, “Biomaterial-associated
thrombosis: roles of coagulation factors, complement, plate-
lets and leukocytes,” Biomaterials, vol. 25, no. 26, pp. 5681–
5703, 2004.
[7] B. Tesfamariam, “Platelet function in intravascular device im-
plant-induced intimal injury,” Cardiovascular Revasculariza-
tion Medicine, vol. 9, no. 2, pp. 78–87, 2008.
[8] L.Li,C.M.Terry,Y.T.E.Shiu,andA.K.Cheung,“Neointimal
hyperplasia associated with synthetic hemodialysis grafts,”
Kidney International, vol. 74, no. 10, pp. 1247–1261, 2008.
[9] V. Mironov, V. Kasyanov, and R. R. Markwald, “Nanotech-
nology in vascular tissue engineering: from nanoscaﬀolding
towards rapid vessel biofabrication,” Trends in Biotechnology,
vol. 26, no. 6, pp. 338–344, 2008.
[10] J. Hoﬀmann, J. Groll, J. Heuts et al., “Blood cell and plasma
protein repellent properties of star-peg-modiﬁed surfaces,”
Journal of Biomaterials Science, Polymer Edition, vol. 17, no.
9, pp. 985–996, 2006.
[11] H.NohandE.A.Vogler,“Volumetricinterpretationofprotein
adsorption: competition from mixtures and the vroman
eﬀect,” Biomaterials, vol. 28, no. 3, pp. 405–422, 2007.
[12] T. A. Horbett, “Proteins: structure, properties and adsorption
to surfaces,” in Biomaterials Science: An Introduction to Mate-
rials in Medicine,B .D .R a tn e r ,A .S .H o ﬀman, F. J. Schoen, and
J. E. Lemons, Eds., pp. 133–141, Academia Press, 1996.
[13] L. Vroman, “Eﬀect of adsorbed proteins on the wettability
of hydrophilic and hydrophobic solids,” Nature, vol. 196, no.
4853, pp. 476–477, 1962.
[14] J. D. Andrade and V. Hlady, “Protein adsorption and materials
biocompatibility: a tutorial review and suggested hypotehe-
ses,” Advances in Polymer Science, pp. 1–63, 1987.
[15] K. L. Menzies and L. Jones, “The impact of contact angle on
the biocompatibility of biomaterials,” Optometry and Vision
Science, vol. 87, no. 6, pp. 387–399, 2010.
[16] S. P. Watson, “Platelet activation by extracellular matrix pro-
teins in haemostasis and thrombosis,” Current Pharmaceutical
Design, vol. 15, no. 12, pp. 1358–1372, 2009.
[17] A. Solouk, B. G. Cousins, H. Mirzadeh, M. Solati-Hashtjin, S.
Najarian, and A. M. Seifalian, “Surface modiﬁcation of poss-
nanocomposite biomaterials using reactive oxygen plasma
treatment for cardiovascular surgical implant applications,”
BiotechnologyandAppliedBiochemistry,vol.58,no.3,pp.147–
161, 2011.
[18] C. M. Nickson, P. J. Doherty, and R. L. Williams, “Novel pol-
ymeric coatings with the potential to control in-stent res-
tenosis—an in vitro study,” Journal of Biomaterials Applica-
tions, vol. 24, no. 5, pp. 437–452, 2010.
[19] A. de Mel, G. Punshon, B. Ramesh et al., “In situ endothe-
lialization potential of a biofunctionalised nanocomposite
biomaterial-based small diameter bypass graft,” Bio-Medical
Materials and Engineering, vol. 19, no. 4-5, pp. 317–331, 2009.
[20] P. W. K¨ ammerer, M. Heller, J. Brieger, M. O. Klein, B.
Al-Nawas, and M. Gabriel, “Immobilisation of linear and
cyclic rgd-peptides on titanium surfaces and their impact on
endothelial cell adhesion and proliferation,” European Cells &
Materials, vol. 21, pp. 364–372, 2011.
[21] M. M. Reynolds and G. M. Annich, “The artiﬁcial endothe-
lium,” Organogenesis, vol. 7, no. 1, pp. 42–49, 2011.
[22] K. Kanie, R. Kato, Y. Zhao, Y. Narita, M. Okochi, and H.
Honda, “Amino acid sequence preferences to control cell-
speciﬁc organization of endothelial cells, smooth muscle cells,
and ﬁbroblasts,” Journal of Peptide Science, vol. 17, no. 6, pp.
479–486, 2011.
[23] M.S.Lord,B.Cheng,S.J.McCarthy,M.Jung,andJ.M.White-
lock, “The modulation of platelet adhesion and activation by
chitosan through plasma and extracellular matrix proteins,”
Biomaterials, vol. 32, no. 28, pp. 6655–6662, 2011.
[24] M. Yaseen, X. Zhao, A. Freund, A. M. Seifalian, and J. R. Lu,
“Surface structural conformations of ﬁbrinogen polypeptides
for improved biocompatibility,” Biomaterials, vol. 31, no. 14,
pp. 3781–3792, 2010.
[25] M. Ahmed, H. Ghanbari, B. G. Cousins, G. Hamilton, and
A. M. Seifalian, “Small calibre polyhedral oligomeric sil-
sesquioxanenanocompositecardiovasculargrafts:inﬂuenceof
porosity on the structure, haemocompatibility and mechani-
cal properties,” Acta Biomaterialia, vol. 7, no. 11, pp. 3857–
3867, 2011.
[26] A. de Mel, G. Jell, M. M. Stevens, and A. M. Seifalian, “Bio-
functionalization of biomaterials for accelerated in situ en-
dothelialization: a review,” Biomacromolecules, vol. 9, no. 11,
pp. 2969–2979, 2008.
[27] R. Y. Kanna, H. J. Salacinski, J. De Groot et al., “The
antithrombogenic potential of a polyhedral oligomeric sil-
sesquioxane (POSS) nanocomposite,” Biomacromolecules, vol.
7, no. 1, pp. 215–223, 2006.
[28] R. Y. Kannan, H. J. Salacinski, M. Odlyha, P. E. Butler, and
A. M. Seifalian, “The degradative resistance of polyhedral
oligomeric silsesquioxane nanocore integrated polyurethanes:
an in vitro study,” Biomaterials, vol. 27, no. 9, pp. 1971–1979,
2006.
[29] H. Ghanbari, A. de Mel, and A. M. Seifalian, “Cardiovascular
application of polyhedral oligomeric silsesquioxane nanoma-
terials: a glimpse into prospective horizons,” International
Journal of Nanomedicine, vol. 6, pp. 775–786, 2011.
[30] A. Wilson, P. E. Butler, and A. M. Seifalian, “Adipose-derived
stem cells for clinical applications: a review,” Cell Proliferation,
vol. 44, no. 1, pp. 86–98, 2011.
[ 3 1 ]K .S a h a ,J .F .P o l l o c k ,D .V .S c h a ﬀer, and K. E. Healy, “De-
signing synthetic materials to control stem cell phenotype,”
Current Opinion in Chemical Biology, vol. 11, no. 4, pp. 381–
387, 2007.
[32] N. S. Hwang, S. Varghese, and J. Elisseeﬀ, “Controlled dif-
ferentiation of stem cells,” Advanced Drug Delivery Reviews,
vol. 60, no. 2, pp. 199–214, 2008.
[ 3 3 ]E .D a w s o n ,G .M a p i l i ,K .E r i c k s o n ,S .T a q v i ,a n dK .R o y ,
“Biomaterials for stem cell diﬀerentiation,” Advanced Drug
Delivery Reviews, vol. 60, no. 2, pp. 215–228, 2008.
[34] C. Chai and K. W. Leong, “Biomaterials approach to expand
and direct diﬀerentiation of stem cells,” Molecular Therapy,
vol. 15, no. 3, pp. 467–480, 2007.
[35] N.Alobaid,H.J.Salacinski,K.M.Salesetal.,“Nanocomposite
containing bioactive peptides promote endothelialisation by
circulating progenitor cells: an in vitro evaluation,” European
JournalofVascularandEndovascularSurgery,v ol.32,no .1,pp .
76–83, 2006.
[ 3 6 ] D .C .M i l l e r ,T .J .W e b s t e r ,a n dK .M .H a b e r s t r o h ,“ T e c h n o l o g -
ical advances in nanoscale biomaterials: the future of synthetic8 International Journal of Biomaterials
vascular graft design,” Expert Review of Medical Devices, vol. 1,
no. 2, pp. 259–268, 2004.
[ 3 7 ]D .C .M i l l e r ,K .M .H a b e r s t r o h ,a n dT .J .W e b s t e r ,“ M e c h -
anism(s) of increased vascular cell adhesion on nanostruc-
turedpoly(lactic-co-glycolicacid)ﬁlms,”JournalofBiomedical
Materials Research, vol. 73, no. 4, pp. 476–484, 2005.
[ 3 8 ]D .C .M i l l e r ,K .M .H a b e r s t r o h ,a n dT .J .W e b s t e r ,“ P L G A
nanometer surface features manipulate ﬁbronectin interac-
tions for improved vascular cell adhesion,” Journal of Biomed-
ical Materials Research, vol. 81, no. 3, pp. 678–684, 2007.
[39] R. J. McMurray, N. Gadegaard, P. M. Tsimbouri et al., “Na-
noscale surfaces for the long-term maintenance of mesenchy-
mal stem cell phenotype and multipotency,” Nature Materials,
vol. 10, no. 8, pp. 637–644, 2011.
[40] L. E. McNamara, R. J. McMurray, M. J. Biggs, F. Kantawong,
R. O. Oreﬀo, and M. J. Dalby, “Nanotopographical control
of stem cell diﬀerentiation,” Journal of Tissue Engineering, vol.
2010, article 120623, 2010.
[41] A. de Mel, C. Bolvin, M. Edirisinghe, G. Hamilton, and A.
M. Seifalian, “Development of cardiovascular bypass grafts:
endothelialization and applications of nanotechnology,” Ex-
pert Review of Cardiovascular Therapy, vol. 6, no. 9, pp. 1259–
1277, 2008.
[42] M. Loizidou and A. M. Seifalian, “Nanotechnology and its
applications in surgery,” British Journal of Surgery, vol. 97, no.
4, pp. 463–465, 2010.
[43] Q. P. Pham, U. Sharma, and A. G. Mikos, “Electrospinning
of polymeric nanoﬁbers for tissue engineering applications: a
review,”TissueEngineering,vol.12,no.5,pp.1197–1211,2006.
[44] R. Murugan and S. Ramakrishna, “Nano-featured scaﬀolds
for tissue engineering: a review of spinning methodologies,”
Tissue Engineering, vol. 12, no. 3, pp. 435–447, 2006.
[45] J. J. Norman and T. A. Desai, “Methods for fabrication of
nanoscale topography for tissue engineering scaﬀolds,” Annals
of Biomedical Engineering, vol. 34, no. 1, pp. 89–101, 2006.
[46] H. Perea, J. Aigner, J. T. Heverhagen, U. Hopfner, and E.
Wintermantel, “Vascular tissue engineering with magnetic
nanoparticles:seeingdeeper,”JournalofTissueEngineeringand
Regenerative Medicine, vol. 1, no. 4, pp. 318–321, 2007.
[47] A. De Mel, F. Murad, and A. M. Seifalian, “Nitric oxide: a
guardian for vascular grafts?” Chemical Reviews, vol. 111, no.
9, pp. 5742–5767, 2011.
[48] A. G. Kidane, H. Salacinski, A. Tiwari, K. R. Bruckdorfer,
and A. M. Seifalian, “Anticoagulant and antiplatelet agents:
their clinical and device application(s) together with usages to
engineer surfaces,” Biomacromolecules, vol. 5, no. 3, pp. 798–
813, 2004.